In:
Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, University of Toronto Press Inc. (UTPress), Vol. 5, No. 4 ( 2020-12-31), p. 214-222
Abstract:
We provide an update to the Association of Medical Microbiology and Infectious Disease Canada foundation guidance for the upcoming 2020–2021 influenza season in Canada. Important issues for this year include the implications of co-circulation of SARS-CoV-2, the role of diagnostic testing, and a restatement of dosing and administration recommendations for neuraminidase inhibitors in various age groups and underlying health conditions. Although peramivir and baloxivir are now licensed in Canada, neither is currently marketed, so this guidance focuses on further optimizing the use of oseltamivir and zanamivir.
Type of Medium:
Online Resource
ISSN:
2371-0888
DOI:
10.3138/jammi-2020-11-02
Language:
English
Publisher:
University of Toronto Press Inc. (UTPress)
Publication Date:
2020
detail.hit.zdb_id:
3041436-2